Objective
Solid tumors, in particular metastatic ones, represent unmet clinical needs and the second cause of death worldwide. Oncolytic viruses (OVs) kill tumors and spare normal cells. They are a distinct class of novel anti-cancer agents, frequently administered by intratumoral injection. A Holy Grail in the innovation of OVs is the possibility to administer them by systemic, e.g. intravenous injection, so that in the human body OVs search for metastases and scavenge them. The systemic delivery of OVs tackles societal challenges as it meets the needs of metastatic patients, those who die of cancer and need innovative therapies most.
The Principal Investigator has generated a family of innovative oncolytic herpesviruses (ReHVs) which specifically target HER2-positive tumors (HER2-ReHVs). In preclinical studies HER2-ReHVs exhibit high specificity for HER2-positive cancers, high anti-tumor efficacy also against metastatic tumors, vaccinate against metastatic-like tumors, and are highly safe. These properties position ReHVs for systemic delivery. The ReHV technology is protected by a portfolio of patents. The objectives of this Proposal are twofold. Firstly, to improve the systemic delivery of ReHVs by identifying the obstacles that constrain such administration, to develop novel strategies to overcome them, including high-risk high-gain modifications that make ReHVs better suited for the systemic delivery. Secondly, to carry out initiatives for the technological transfer, i.e. development and commercialization of ReHVs. These include the detailed planning of activities to take ReHVs to the authorization for a First-in-Human clinical experimentation, to develop a business plan and carry out OV market analysis and search for investors. By combining the Development and commercialization initiatives with the technological advancements, this POC is expected to achieve the broader objective of progressing ReHVs into clinical experimentation and ultimately to bring them to patients
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences microbiology virology
- medical and health sciences clinical medicine oncology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.1 - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2022-POC1
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
40138 Bologna
Italy
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.